(i) 3A associated constructs
To construct expression plasmids pcDNA-3A(O99) and pcDNA-3A(O97), the 3A genes for O/TAW/97 (GenBank No. AY593835.1) and O/TAW/99 (GenBank No. AJ539136.1) were amplified (Phusion™ High-Fidelity DNA Polymerase, Thermo Scientific) from the O/TAW/97 cDNA pool and synthesized correspondingly. The 3A genes were subcloned into pcDNA-3.1(+) using HindIII and XhoI sites with C-terminal His tag fusion; the endogenous NheI site within O/97 3A was further removed by site-direct mutagenesis without changing the amino acid sequence (GENEART site-directed mutagenesis system, Invitrogen). On the other hand, the mGFP genes were inserted into pcDNA-3.1(+) with NheI/XhoI sites, in which a HindIII site was inserted between the mGFP gene and XhoI site, generating pcDNA-mGFP. The 3A genes from pcDNA-3A(O99) or pcDNA-3A(O97) were subcloned into pcDNA-mGFP by HindIII/XhoI, generating pcDNA-mGFP-3A(O99) and pcDNA-mGFP-3A(O97).
The d1D-2A-eGFP (d1A: deleted 1D gene; the last 33 nt of VP1 gene from O/TAW/97) cassette flanked by NheI-BamHI and HindIII-XhoI was inserted into pcDNA-3.1(+) by NheI and XhoI restriction enzymes, generating pcDNA-2AeGFP vector. Next, various truncations of 3A genes were inserted between HindIII/XhoI (or HindIII/XbaI) sites. For 3A-eGFP2A constructs, the genes and restriction sites from pcDNA-2AeGFP were rearranged. The d1D2A gene was subcloned into pcDNA-3.1(+) with NheI/XhoI sites, adding BamHI site to the 5’ end of the d1D2A gene. Next, eGFP gene was inserted into the plasmid by NheI/BamHI, and a HindIII site was added to the 5’ end of the eGFP gene. The variant truncated 3A genes were further inserted by NheI/HindIII.
The APEX2 vector was purchased and inserted into pcDNA-3.1(+) by NheI and XhoI. The indicated truncated or full-length 3A genes were inserted by XhoI and XbaI. For GST fusion plasmids, GFP genes in variant mGFP- version and -eGFP2A versions were replaced by GST genes using NheI/HindIII and HindIII/XhoI enzymes respectively.
(iii) Others
The mCherry gene, flanked by peptide sequences of calreticulin and KDEL motif, was inserted into pcDNA-3.1(+) by NheI and HindIII to generate pcDNA-mCherry-ER. The plasmid for expressing mCherry-LC3B was a gift from David Rubinsztein (Addgene plasmid # 40827). The 2B and 2C genes were amplified from the O/TAW/97 cDNA pool and then subcloned into pcDNA-3.1(+) for pcDNA-2B and pcDNA-2C. These two plasmids were further inserted by mGFP genes by NheI and KpnI, generating pcDNA-mGFP-2B and pcDNA-mGFP-2C.
Monoclonal antibody preparation. BALB/c mice were immunized by purified SUMO-3ABC (O/97) and GST-3ABC (O/99), expressed from E. coli. Immunized spleen cells were fused with SP2/0-Ag14 myeloma cells. After 1–2 weeks, hybridoma supernatants were screened by IFA with 3A(O99), 3A(O97), and FMDV acetone-fixed cell plates. After limited dilution of more than twice, positive clones were further characterized. QA2, PA1, and T10E were selected for this study. Their isotypes all belonged to IgG2a/κ. The purified monoclonal antibodies were obtained as in a previous study 55. The hybridoma was inoculated intraperitoneally into BALB/c for ascetic fluid and purified by Protein G (GE Healthcare). The purified antibodies were further conjugated with fluorescent dye Dylight488 (Abcam, ab201799) following the manufacturer’s instructions.
Western blotting. Equal volumes of cell lysates oamr elution from co-immunoprecipitation (co-IP) were mixed with sample loading buffer (Bionovas, FA0020) and incubated at 95˚C for 5 min. Samples were separated by 13.5% SDS-PAGE, transferred to nitrocellulose membrane (PALL, 79548), and blocked by 5% (w/v) skim milk in PBST at room temperature (RT) for 30 min. The proteins on the membranes were detected by the indicated antibodies overnight in 4˚C and corresponding horseradish peroxidase (HRP) conjugated secondary antibodies at RT for 1 h. Given that bands were masked by the light and heavy chains of antibodies used in the co-IP step, secondary antibodies against native antibodies (Abcam, ab131366, which could not recognize mouse IgG1) or specific mouse native antibodies (Abcam, ab131368) were used for elution samples.
Immunofluorescence assay and confocal live-cell imaging. PK-15 or A549 cells, grown on a confocal µ-dish (ibidi, IB-81156), were transfected with indicated plasmids for 24 h. For standard IFA protocols, cells were fixed by 4% paraformaldehyde in PBS for 15 min at 37˚C and further permeabilized by 0.5% TX-100 for 5 min at RT. For examination of the 3A protein topology, fixed cells were permeabilized by 50 µg ml−1 digitonin for 5 min at RT. After being washed with PBS three times, samples were incubated with primary antibodies for 2 h at 37˚C, followed by incubation with appropriate secondary antibodies for 1 h at 37˚C. When double labeling was performed, both antibodies were added together. The nucleus was stained with Hoechst stain (Invitrogen, H3569) for 15 min at 37˚C. All imaging was performed under an Olympus IX-83 microscope connected to a CMOS color camera. Live cells were maintained on the microscope stage at 37˚C.
Autophagy induction. PK-15 cells in 24-well plates were transfected for 21 h. After washing with PBS, the medium was replaced with fresh DMEM, DMEM with 100 nM rapamycin, or starvation medium (20 mM HEPES, pH 7.4, 140 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM glucose, 1% BSA) for 3 h. The cells were collected by 50 µl RIPA buffer (Bio Basic, RB4478); 5 µl of cell lysates were analyzed by 6M urea 13.5% SDS gel, followed by western blotting to detect LC3BI and LC3BII.
Transmission electron microscopy and electron tomography. PK-15 cells were seeded on the Aclar film (Electron Microscopy Science) within 6-well plates. After transfection for indicated plasmids containing APEX2 fusion protein gene for 24 h, the cells were rinsed by PBS, followed by 2% glutaraldehyde fixation in 0.1 M phosphate buffer (PB, pH 7.3) for 1 h on ice. After five times of washing with PBS, 20 mM glycine in PBS was added for 5 min to quench free aldehyde groups. After another five times of washing, cells were incubated with DAB solution with H2O2 (5 min for APEX2-3A, 15 min for APEX2-NHR, 30 min for APEX2-N2HRC, and 30 min for APEX2-N2HRC1). The cells were further rinsed in 0.1M PB (2 min x 5 times) and immersed into 2% Osmium tetroxide in 0.1 M PB for 30 min. The cells were then rinsed in distilled water (2 min x 5 times) before overnight staining in a 2% aqueous solution of uranyl acetate. The cells in the monolayer were further subjected to a standard protocol of dehydration and embedding (Spurr’s medium) for TEM imaging. The specimen blocks were checked and trimmed under a stereomicroscope, and ultra-thin sections (70 nm) were obtained from the area with positive signals (dark cells). The sections were observed using a transmission electron microscope (TEM, FEI Tecnai G2 TF20 Super TWIN) operating at 120 kV. For electron tomography, serial sections (200 nm) through the APEX2-positive cells were obtained56. Double-tilt electron tomography was performed with the TEM (FEI Tecnai G2 TF20) operating at 200 kV. The structures of organelles were depicted by Amira/Avizo software.
Recombinant vaccinia expression system. The protocol followed that of a previous study 57. HTK− cells were seeded in 6-well plates for 1 day, followed by vTF7-3 infection for production of T7 polymerase within cells for 1 h. The indicated plasmids, containing T7 promoter, were transfected to the cells by using TurboFect (Thermo Scientific). After 20–24 h, cells were ruptured by freeze-thaw cycles for 3 times in 500 µl PBS with protease inhibitor (Millipore, 539134). Finally, the cell debris was removed by 10,000 g centrifugation for 20 min.
Immuno-precipitation assay. For each sample, 1 µg anti-FLAG antibody (Sigma, F1804) or PA1 MAb was incubated with 10 µl Protein G Mag Sepharose (GE Healthcare) in 500 µl binding buffer (50mM Tris, pH 7.5, 150 mM NaCl) with slow end-over-end mixing for 1 h at RT. Cell lysates that came from the vTF7-3 expression system or transfected PK-15 cells were applied to co-immunoprecipitation assay. For the vTF7-3 expression system, a 200 µl sample was incubated with anti-FLAG antibody-magnetic bead overnight after removal of the binding buffer. For transfected PK-15 cells, which were harvested by 200 µl RIPA buffer in each well of 6-well plates, 180 µl samples were applied. After mixing overnight at 4˚C, the magnetic bead was washed by PBS or RIPA three times. After replacement with a clean Eppendorf tube, the bead was washed by PBS again. Finally, the sample was eluted by 20 µl 2% SDS and analyzed by western blotting.
Knockdown assay. A549 cells were seeded in a 6-well plate and then transfected with indicated plasmids expressing shRNA, including pLAS2w.Ppuro (empty vector), Sar1-1 (target: CCAGTTCCTAGGACTCTACAA), Sar1-2 (target: CGTGAGATATTTGGGCTTTAT), Sec12-0 (target: GCTGGCCTAAAGATGCAATAA) and Sec12-4 (target: GTGTGCTTCAACCACGATAAT). The plasmids were purchased from National RNAi Core Facility in Taiwan. After 24 h post transfection, cells were selected by 1 µg ml−1 puromycin for 3–4 days and maintained in DMEM with 0.5 µg ml−1 puromycin for more than 2 weeks. For siRNA, cells were seeded in a 24-well plate 1 day before siRNA transfection, in accordance with the manufacturer’s instructions for Lipofectamine MessengerMAX Reagent (Thermo Scientific, LMRNA). The target sequence for non-target and Sar1 siRNA was as follows: non-target (UUCUCCGAACGUGUCACGU) and Sar1 (CCAGUUCCUAGGACUCUACAA), purchased from Biotools. To elevate the knockdown efficiency, A549 cells were transfected repeatedly after 24 h siRNA transfection. After 6 h post last siRNA transfection, pcDNA-mGFP-N2HRC1 were transfected to the cells.